title: [The use of holoxan (iphosphamide) in malignant tumors].
abstract: A clinical trial of holoxan in combination with a urological protector--uromitexan--was carried out. Response was observed in 26.3% of patients with lung cancer. The drug was effective in cases of soft tissue sarcoma and Ewing's sarcoma.
authors.forename: N I
authors.initials: NI
authors.lastname: Perevodchikova
authors.forename: N F
authors.initials: NF
authors.lastname: Orel
authors.forename: N V
authors.initials: NV
authors.lastname: Trofimova
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D015080:Mesna / Q000627:therapeutic use; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D012074:Remission Induction
chemical_list: D015080:Mesna; D007069:Ifosfamide
vernacular_title: Primenenie goloksana (ifosfamida) pri zlokachestvennykh opukholiakh.